|
Title
Formulation and evaluation of transferosomal buccal film containing empagliflozin – an antidiabetic agent
Authors
ASHISH P. GORLE, JANHAVI WAGH and SWATI RAYSING
Received
July 9, 2026
Published
Volume 60 Issue 7-8 July-August
Keywords
transferosomes, buccal film, SGLT2 inhibitor, Central Composite Design, in vitro release, in vivo
pharmacokinetic evaluation, stability studies
Abstract
Diabetes mellitus is one of the most difficult chronic diseases around the world, and it is as important to discover ways
to better deliver antidiabetic drugs as it is to discover them. Empagliflozin is a selective SGLT2 inhibitor that has a
restricted therapeutic potential when administered as an oral tablet. To overcome this limitation, it was chosen in this
study as a drug to deliver through a transferosomal buccal film. Lipid vesicles (Lipoid S100 and Tween 80) were prepared
by the ethanol injection method and optimised using a Central Composite Design. The mean particle size, entrapment
efficiency and the zeta potential of the optimized transferosomes were found to be 119 nm, 86% and -28.3 mV,
respectively (Batch F4). They were then incorporated into a film prepared by the solvent casting technique using
mucoadhesive materials, such as HPMC E5, PVP K30 and PEG 400. The results indicated that Batch B3 was the best
batch having the drug content of 97.67%, moisture content of 4.46% and folding endurance of 127. The optimized
formulation released 97.85% of drug in vitro in 60 minutes and had ex-vivo buccal permeation that was 18.93% higher
than that of a plain film, having a zero-order release profile; also, it was found stable when kept at different temperatures.
Most importantly, in-vivo pharmacokinetic evaluation in Sprague Dawley rats further confirmed enhanced systemic
absorption, with the transferosomal film showing markedly higher bioavailability (AUC₀₋∞: 8.706 vs. 5.519 µg·h/mL)
and Cmax (0.93 vs. 0.56 µg/mL) relative to the plain buccal film.
Link
https://doi.org/10.35812/CelluloseChemTechnol.2026.60.71
|